The FINANCIAL — Bayer HealthCare and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on November 22 announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think they know why. Photo by Adobe Stock/HealthDay News Current treatments ...

Aflibercept is a soluble decoy fusion protein that binds all isoforms of vascular endothelial growth factor (VEGF) with a greater binding affinity than ranibizumab. Intravitreal aflibercept is US Food ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Of three ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

A Massachusetts General Hospital (MGH) investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of ...

The MarketWatch News Department was not involved in the creation of this content. Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

Global Ophthalmology Drugs Market OutlookThe global ophthalmology drugs market is forecasted to expand at a CAGR of nearly 8% ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration-- and researchers now think they know why. Wet AMD is caused by an overgrowth of blood vessels in the ...